vimarsana.com
Home
Live Updates
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU) : vimarsana.com
Japan First in the World to Approve Dupixent® (dupilumab) for Chronic Spontaneous Urticaria (CSU)
Approval based on results from Phase 3 trial showing Dupixent significantly reduced itch compared to placebo CSU is the fifth approved indication for Dupixent in Japan and the sixth indication for...
Related Keywords
Japan
,
Paris
,
France General
,
France
,
Japanese
,
Sally Bain
,
Evan Berland
,
Arnaud Delepine
,
Nathalie Pham
,
Georged Yancopoulos
,
Corentine Driancourt
,
Regeneron Velocimmune
,
Tarik Elgoutni
,
Felix Lauscher
,
Vesna Tosic
,
Ilana Yellen
,
Eva Schaefer Jansen
,
Linkedin
,
Regeneron Genetics Center
,
Dupilumab Development Program
,
Exchange Commission
,
Ministry Of Health
,
Euronext
,
Regeneron Pharmaceuticals Inc
,
Regeneron Velocimmune Technology
,
Nasdaq
,
Chief Scientific Officer George
,
Nasal Polyposis
,
Prescribing Information
,
Forward Looking Statements
,
Regeneron Pharmaceuticals
,
Product Candidates
,
Private Securities Litigation Reform Act
,
Statement Regarding Forward Looking
,
Markets
,
vimarsana.com © 2020. All Rights Reserved.